TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET 74
1.4 CURRENCY AND PRICING 76
1.5 LIMITATIONS 76
1.6 MARKETS COVERED 76
2 MARKET SEGMENTATION 80
2.1 MARKETS COVERED 80
2.2 GEOGRAPHICAL SCOPE 81
2.3 YEARS CONSIDERED FOR THE STUDY 82
2.4 DBMR TRIPOD DATA VALIDATION MODEL 83
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
2.6 MULTIVARIATE MODELLING 87
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 87
2.8 MARKET APPLICATION COVERAGE GRID 88
2.9 DBMR MARKET POSITION GRID 89
2.10 VENDOR SHARE ANALYSIS 90
2.11 SECONDARY SOURCES 91
2.12 ASSUMPTIONS 91
3 EXECUTIVE SUMMARY 92
4 PREMIUM INSIGHTS 94
4.1 PESTEL ANALYSIS 95
4.2 PORTER'S 5 FORCES 96
5 INDUSTRY INSIGHTS 97
6 REGULATORY FRAMEWORK 99
6.1 REGULATORY SCENARIO BY U.S. FDA 99
6.2 REGULATORY SCENARIO IN U.S. 99
6.3 REGULATORY SCENARIO IN EUROPE 100
6.4 REGULATORY SCENARIO IN CANADA 100
6.5 REGULATORY SCENARIO IN AUSTRALIA 100
7 MARKET OVERVIEW 101
7.1 DRIVERS 103
7.1.1 RISING CASES OF COLORECTAL CANCER NORTH AMERICALY 103
7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING 103
7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES 104
7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS 104
7.2 RESTRAINTS 104
7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES 104
7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES 105
7.3 OPPORTUNITIES 105
7.3.1 INCREASE IN SCREENING PROCEDURES 105
7.3.2 RISING TECHNICAL ADVANCEMENTS 106
7.3.3 STRATEGIC INITIATIVES 106
7.4 CHALLENGES 107
7.4.1 LACK OF SKILLED PROFESSIONALS 107
7.4.2 LOW EFFICIENCY 107
8 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE 108
8.1 OVERVIEW 109
8.2 LATERAL FLOW IMMUNO-FOB TEST KITS 112
8.3 IMMUNO-FOB AGGLUTINATION TEST KITS 112
8.4 IMMUNO-FOB ELISA TEST KITS 113
8.5 GUAIAC FOB STOOL TEST 114
8.5.1 KITS 115
8.5.1.1 GUAIAC SLIDES 115
8.5.1.1.1 25 PACKAGE 115
8.5.1.1.2 20 PACKAGE 115
8.5.1.1.3 OTHERS 115
8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER 116
8.5.1.2.1 SENSITIVITY IS 50NG/ML 116
8.5.1.2.1.1 25 PACKAGE 116
8.5.1.2.1.2 20 PACKAGE 116
8.5.1.2.1.3 OTHERS 117
8.5.1.2.2 SENSITIVITY IS 75NG/ML 117
8.5.1.2.2.1 25 PACKAGE 117
8.5.1.2.2.2 20 PACKAGE 117
8.5.1.2.2.3 OTHERS 117
8.5.1.2.3 OTHERS 117
8.5.1.3 OTHERS 118
8.5.2 REAGENTS 118
8.5.2.1 HYDROGEN PEROXIDE 118
8.5.2.2 OTHERS 118
8.6 FLUSHABLE REAGENT PAD OR TISSUE 118
8.7 OTHERS 119
9 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION 120
9.1 OVERVIEW 121
9.2 COLORECTAL CANCER SCREENING 124
9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS 125
9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS 125
9.2.3 IMMUNO-FOB ELISA TEST KITS 125
9.2.4 GUAIAC FOB STOOL TEST 125
9.2.5 FLUSHABLE REAGENT PAD OR TISSUE 125
9.2.6 OTHERS 125
9.3 CONCERN FOR GASTROINTESTINAL BLEEDING 125
9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS 126
9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS 126
9.3.3 IMMUNO-FOB ELISA TEST KITS 126
9.3.4 GUAIAC FOB STOOL TEST 127
9.3.5 FLUSHABLE REAGENT PAD OR TISSUE 127
9.3.6 OTHERS 127
9.4 POLYPS 127
9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS 128
9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS 128
9.4.3 IMMUNO-FOB ELISA TEST KITS 128
9.4.4 GUAIAC FOB STOOL TEST 128
9.4.5 FLUSHABLE REAGENT PAD OR TISSUE 128
9.4.6 OTHERS 128
9.5 DIVERTICULOSIS 129
9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS 130
9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS 130
9.5.3 IMMUNO-FOB ELISA TEST KITS 130
9.5.4 GUAIAC FOB STOOL TEST 130
9.5.5 FLUSHABLE REAGENT PAD OR TISSUE 130
9.5.6 OTHERS 130
9.6 ULCERS 130
9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS 131
9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS 131
9.6.3 IMMUNO-FOB ELISA TEST KITS 131
9.6.4 GUAIAC FOB STOOL TEST 132
9.6.5 FLUSHABLE REAGENT PAD OR TISSUE 132
9.6.6 OTHERS 132
9.7 HAEMORRHOIDS 132
9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS 133
9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS 133
9.7.3 IMMUNO-FOB ELISA TEST KITS 133
9.7.4 GUAIAC FOB STOOL TEST 133
9.7.5 FLUSHABLE REAGENT PAD OR TISSUE 133
9.7.6 OTHERS 133
9.8 COLITIS 134
9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS 135
9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS 135
9.8.3 IMMUNO-FOB ELISA TEST KITS 135
9.8.4 GUAIAC FOB STOOL TEST 135
9.8.5 FLUSHABLE REAGENT PAD OR TISSUE 135
9.8.6 OTHERS 135
9.9 ANEMIA 135
9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS 136
9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS 136
9.9.3 IMMUNO-FOB ELISA TEST KITS 136
9.9.4 GUAIAC FOB STOOL TEST 137
9.9.5 FLUSHABLE REAGENT PAD OR TISSUE 137
9.9.6 OTHERS 137
9.10 OTHERS 137
10 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER 138
10.1 OVERVIEW 139
10.2 DIAGNOSTIC LABORATORIES 142
10.3 HOSPITALS 142
10.4 SPECIALITY CLINICS 143
10.5 OTHERS 144
11 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL 145
11.1 OVERVIEW 146
11.2 DIRECT TENDER 149
11.3 RETAIL SALE 149
11.4 E-COMMERCE 150
11.5 OTHERS 151
12 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY REGION 152
12.1 NORTH AMERICA 153
12.1.1 U.S. 166
12.1.2 CANADA 174
12.1.3 MEXICO 182
13 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE 190
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 190
14 SWOT ANALYSIS 191
15 COMPANY PROFILE 192
15.1 QUIDEL CORPORATION 192
15.1.1 COMPANY SNAPSHOT 192
15.1.2 REVENUE ANALYSIS 192
15.1.3 COMPANY SHARE ANALYSIS 193
15.1.4 PRODUCT PORTFOLIO 193
15.1.5 RECENT DEVELOPMENT 193
15.2 WONDFO. 194
15.2.1 COMPANY SNAPSHOT 194
15.2.2 COMPANY SHARE ANALYSIS 194
15.2.3 PRODUCT PORTFOLIO 195
15.2.4 RECENT DEVELOPMENT 195
15.3 SIEMENS HEALTHCARE GMBH 196
15.3.1 COMPANY SNAPSHOT 196
15.3.2 REVENUE ANALYSIS 196
15.3.3 COMPANY SHARE ANALYSIS 197
15.3.4 RODUCT PORTFOLIO 197
15.3.5 RECENT DEVELOPMENT 197
15.4 EIKEN CHEMICAL CO., LTD. 198
15.4.1 COMPANY SNAPSHOT 198
15.4.2 REVENUE ANALYSIS 198
15.4.3 COMPANY SHARE ANALYSIS 199
15.4.4 PRODUCT PORTFOLIO 199
15.4.5 RECENT DEVELOPMENT 199
15.5 BIOHIT OYJ 200
15.5.1 COMPANY SNAPSHOT 200
15.5.2 REVENUE ANALYSIS 200
15.5.3 COMPANY SHARE ANALYSIS 201
15.5.4 PRODUCT PORTFOLIO 201
15.5.5 RECENT DEVELOPMENT 201
15.6 ACCUBIOTECH CO LTD 202
15.6.1 COMPANY SNAPSHOT 202
15.6.2 PRODUCT PORTFOLIO 202
15.6.3 RECENT DEVELOPMENT 202
15.7 ACCUQUIK TEST KITS 203
15.7.1 COMPANY SNAPSHOT 203
15.7.2 PRODUCT PORTFOLIO 203
15.7.3 RECENT DEVELOPMENT 203
15.8 AIDIAN 204
15.8.1 COMPANY PROFILE 204
15.8.2 PRODUCT PORTFOLIO 204
15.8.3 RECENT DEVELOPMENT 204
15.9 ALFA SCIENTIFIC DESIGNS, INC. 205
15.9.1 COMPANY SNAPSHOT 205
15.9.2 PRODUCT PORTFOLIO 205
15.9.3 RECENT DEVELOPMENT 205
15.10 APACOR LIMITED 206
15.10.1 COMPANY SNAPSHOT 206
15.10.2 PRODUCT PORTFOLIO 206
15.10.3 RECENT DEVELOPMENT 206
15.11 BIOPANDA REAGENTS LTD 207
15.11.1 COMPANY SNAPSHOT 207
15.11.2 PRODUCT PORTFOLIO 207
15.11.3 RECENT DEVELOPMENT 207
15.12 BODITECH MED INC. 208
15.12.1 COMPANY SNAPSHOT 208
15.12.2 PRODUCT PORTFOLIO 208
15.12.3 RECENT DEVELOPMENT 208
15.13 CENOGENICS CORPORATION 209
15.13.1 COMPANY SNAPSHOT 209
15.13.2 PRODUCT PORTFOLIO 209
15.13.3 RECENT DEVELOPMENT 209
15.14 CERTEST BIOTEC. 210
15.14.1 COMPANY SNAPSHOT 210
15.14.2 PRODUCT PORTFOLIO 210
15.14.3 RECENT DEVELOPMENT 210
15.15 CTK BIOTECH, INC. 211
15.15.1 COMPANY SNAPSHOT 211
15.15.2 PRODUCT PORTFOLIO 211
15.15.3 RECENT DEVELOPMENT 211
15.16 EDP BIOTECH 212
15.16.1 COMPANY SNAPSHOT 212
15.16.2 PRODUCT PORTFOLIO 212
15.16.3 1.16.3 RECENT DEVELOPMENT 212
15.17 EPITOPE DIAGNOSTICS, INC. 213
15.17.1 COMPANY SNAPSHOT 213
15.17.2 PRODUCT PORTFOLIO 213
15.17.3 RECENT DEVELOPMENT 213
15.18 EUROLYSER DIAGNOSTICA GMBH 214
15.18.1 COMPANY SNAPSHOT 214
15.18.2 PRODUCT PORTFOLIO 214
15.18.3 RECENT DEVELOPMENT 214
15.19 FIRSTEP 215
15.19.1 COMPANY SNAPSHOT 215
15.19.2 PRODUCT PORTFOLIO 215
15.19.3 RECENT DEVELOPMENT 215
15.20 HANGZHOU CLONGENE BIOTECH CO., LTD 216
15.20.1 COMPANY SNAPSHOT 216
15.20.2 PRODUCT PORTFOLIO 216
15.20.3 RECENT DEVELOPMENT 216
15.21 HUMASIS.COM 217
15.21.1 COMPANY SNAPSHOT 217
15.21.2 PRODUCT PORTFOLIO 217
15.21.3 RECENT DEVELOPMENT 217
15.22 JANT PHARMACAL CORPORATION 218
15.22.1 COMPANY SNAPSHOT 218
15.22.2 PRODUCT PORTFOLIO 218
15.22.3 RECENT DEVELOPMENT 218

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.